Cargando…

Clinical applications of circulating tumor cells in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a highly malignant tumor and ranked as the fourth cause of cancer-related mortality. The poor clinical prognosis is due to an advanced stage and resistance to systemic treatment. There are no obvious clinical symptoms in the early stage and the early diagnosis rate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Yinggang, Dong, Jingqing, Hong, Jinsong, Wang, Bailin, Yan, Yong, Li, Zhiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448983/ https://www.ncbi.nlm.nih.gov/pubmed/36091119 http://dx.doi.org/10.3389/fonc.2022.968591

Ejemplares similares

Laparoscopic versus open pancreaticoduodenectomy for pancreatic and periampullary tumor: A meta-analysis of randomized controlled trials and non-randomized comparative studies
por: Yan, Yong, et al.
Publicado: (2023)

The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype
por: Yu, Jing-Jing, et al.
Publicado: (2021)

Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma
por: Lei, Yongrong, et al.
Publicado: (2021)

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Ye, Ke, et al.
Publicado: (2022)

Measurement of Circulating Tumor Cells to Track Hepatocellular Carcinoma Progression After Liver Transplantation-Case Report
por: Deng, Yuan, et al.
Publicado: (2021)

Circulating tumor cell associated white blood cell cluster as a biomarker for metastasis and recurrence in hepatocellular carcinoma
por: Chen, Jing, et al.
Publicado: (2022)

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022)

Detection Methods and Clinical Applications of Circulating Tumor Cells in Breast Cancer
por: Zhang, Hongyi, et al.
Publicado: (2021)

Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma
por: Yang, Jin-Cui, et al.
Publicado: (2022)

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
por: Yang, Xiao, et al.
Publicado: (2022)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma
por: Luo, Qiong, et al.
Publicado: (2020)

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)

Guiding Value of Circulating Tumor Cells for Preoperative Transcatheter Arterial Embolization in Solitary Large Hepatocellular Carcinoma: A Single-Center Retrospective Clinical Study
por: Zhang, Qiao, et al.
Publicado: (2022)

Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma
por: Huang, Zi-Li, et al.
Publicado: (2022)

WTAP Is Correlated With Unfavorable Prognosis, Tumor Cell Proliferation, and Immune Infiltration in Hepatocellular Carcinoma
por: Liang, Linjun, et al.
Publicado: (2022)

Epithelial-mesenchymal transition classification of circulating tumor cells predicts clinical outcomes in progressive nasopharyngeal carcinoma
por: Wei, Jiazhang, et al.
Publicado: (2022)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Correlation Between Circulating Tumor Cell DNA Genomic Alterations and Mesenchymal CTCs or CTC-Associated White Blood Cell Clusters in Hepatocellular Carcinoma
por: Wang, Chunming, et al.
Publicado: (2021)

Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
por: Li, Jie, et al.
Publicado: (2018)

Circulating Tumor Cells: A Promising Biomarker in the Management of Nasopharyngeal Carcinoma
por: Wu, Jiangtao, et al.
Publicado: (2021)

Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma
por: Block, Timothy, et al.
Publicado: (2022)

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma
por: You, Junqi, et al.
Publicado: (2023)

Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges
por: Santoni, Matteo, et al.
Publicado: (2019)

Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma
por: Li, Wei, et al.
Publicado: (2019)

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
por: Yang, Jialiang, et al.
Publicado: (2021)

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
por: Chen, Siqi, et al.
Publicado: (2023)

Tumor purity–associated genes influence hepatocellular carcinoma prognosis and tumor microenvironment
por: Zhao, Yan, et al.
Publicado: (2023)

Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
por: Wu, Jun-Yi, et al.
Publicado: (2021)

Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
por: Li, Yang, et al.
Publicado: (2022)

Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights
por: Chemi, Francesca, et al.
Publicado: (2021)

Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells
por: Li, Yue, et al.
Publicado: (2022)

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer
por: Fu, Guanghou, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Association Between Circulating Lymphocyte Populations and Outcome After Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma
por: Zhuang, Yuan, et al.
Publicado: (2019)

Circulating Tumor Cells for Glioma
por: Zhang, Huikai, et al.
Publicado: (2021)

Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma
por: Matsushita, Daisuke, et al.
Publicado: (2015)

A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features
por: Liu, Tao, et al.
Publicado: (2023)

Longitudinal Analysis of Circulating Tumor Cells in Colorectal Cancer Patients by a Cytological and Molecular Approach: Feasibility and Clinical Application
por: Hendricks, Alexander, et al.
Publicado: (2021)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qegj2fo2n4ntrugct3pra8h42g